Cargando…

Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag

BACKGROUND & AIMS: Despite limitations, platelet transfusion has been used to minimise bleeding risk in patients with thrombocytopaenia. Lusutrombopag is an oral, thrombopoietin receptor agonist approved for treatment of thrombocytopaenia associated with chronic liver disease in patients undergo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, Robert S., Imawari, Michio, Izumi, Namiki, Osaki, Yukio, Bentley, Roy, Ochiai, Toshimitsu, Kano, Takeshi, Peck-Radosavljevic, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887643/ https://www.ncbi.nlm.nih.gov/pubmed/33644726 http://dx.doi.org/10.1016/j.jhepr.2021.100228

Ejemplares similares

A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation
por: Tateishi, Ryosuke, et al.
Publicado: (2018)

Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child–Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing Surveillance
por: Flamm, Steven L., et al.
Publicado: (2022)

Bleeding events in lusutrombopag‐treated thrombocytopenic patients
por: Giannini, Edoardo Giovanni, et al.
Publicado: (2021)

Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance
por: Sasaki, Ritsue, et al.
Publicado: (2019)

Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L‐PLUS 2)
por: Peck‐Radosavljevic, Markus, et al.
Publicado: (2019)

Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures
por: Takada, Hitomi, et al.
Publicado: (2019)

Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures
por: Orme, Michelle E., et al.
Publicado: (2022)

Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters
por: Katsube, Takayuki, et al.
Publicado: (2020)

A study on prevention of bleeding complications using lusutrombopag for safe RFA in patients with hepatocellular carcinoma with low platelet counts: prospective observational study
por: Yoshida, Hideo, et al.
Publicado: (2023)

Relationship between response to lusutrombopag and splenic volume
por: Uojima, Haruki, et al.
Publicado: (2018)

Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures
por: Ding, Zhenbin, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures
por: Katsube, Takayuki, et al.
Publicado: (2019)

Lusutrombopag as a substitute for platelet transfusion for thrombocytopenia associated with chronic liver disease in a patient undergoing endoscopic spinal surgery: A case report
por: Kaneko, Takeshi, et al.
Publicado: (2021)

Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
por: Sakamaki, Akira, et al.
Publicado: (2017)

Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures
por: Nishida, Yuno, et al.
Publicado: (2020)

Association between the magnitude of periprocedural myocardial injury and prognosis in patients undergoing elective percutaneous coronary intervention
por: Zhou, You, et al.
Publicado: (2021)

Magnitude or Multitude – What Counts?
por: Lachmair, Martin, et al.
Publicado: (2018)

Periprocedural use of avatrombopag for neurosurgical interventions: a strategy to avoid platelet utilization
por: Lim, Ming Y., et al.
Publicado: (2020)

Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, in Rats by UPLC-MS/MS
por: Wang, Bo, et al.
Publicado: (2020)

A cost‐effectiveness analysis of lusutrombopag for thrombocytopenia in patients with chronic liver disease in Japan
por: Miki, Norikane, et al.
Publicado: (2021)

Effects of Lusutrombopag on Post-invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease
por: Yoshida, Manami, et al.
Publicado: (2021)

Periprocedural Variability of Platelet Functions in Carotid Artery Stenting: An Analysis Using VerifyNow
por: Yoshimura, Masataka, et al.
Publicado: (2021)

Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment
por: Sato, Shuichi, et al.
Publicado: (2017)

Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia
por: Ishikawa, Toru, et al.
Publicado: (2019)

Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study
por: Nomoto, Hiroaki, et al.
Publicado: (2020)

A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series
por: Biolato, Marco, et al.
Publicado: (2022)

Drug Therapy for Advanced-Stage Liver Cancer
por: Peck-Radosavljevic, Markus
Publicado: (2014)

Editorial
por: Peck-Radosavljevic, Markus
Publicado: (2020)

Factors associated with periprocedural myocardial infarction
por: Okşul, Metin, et al.
Publicado: (2019)

Periprocedural myocardial injury in the EXCEL trial
por: Bjørnstad, Johannes L, et al.
Publicado: (2020)

Unique characteristics of new complete blood count parameters, the Immature Platelet Fraction and the Immature Platelet Fraction Count, in dengue patients
por: Yasuda, Ikkoh, et al.
Publicado: (2021)

Methotrexate and the platelet count.
por: Ogston, D., et al.
Publicado: (1968)

Advances in Analgosedation and Periprocedural Care for Gastrointestinal Endoscopy
por: Skiljic, Sonja, et al.
Publicado: (2023)

Correlations between High Platelet Reactivity, Extent of Coronary Artery Disease, and Periprocedural Myonecrosis in Patients with Acute Coronary Syndrome
por: Yun, Kyeong Ho, et al.
Publicado: (2017)

Review article: systemic treatment of hepatocellular carcinoma
por: Pinter, Matthias, et al.
Publicado: (2018)

Platelet count and platelet indices in women with preeclampsia
por: AlSheeha, Muneera A, et al.
Publicado: (2016)

An Evaluation of the Accuracy of the Subtraction Method Used for Determining Platelet Counts in Advanced Platelet-Rich Fibrin and Concentrated Growth Factor Preparations
por: Watanabe, Taisuke, et al.
Publicado: (2017)

Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib
por: Sakai, Kazuko, et al.
Publicado: (2015)

Periprocedural considerations of transcatheter aortic valve implantation for anesthesiologists
por: Afshar, Ata Hassani, et al.
Publicado: (2016)

The relevance of periprocedural troponin rise: the never ending story!
por: Fröhlich, Georg Marcus, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jigf19tktc1clqbg7eftbl898s